Antibiotics Apocalypse: Why Big Pharma Abandoned the World's Most Important Drug? | Case study
Think School's case study of the antibiotic apocalypse: superbugs already kill 2-5 million people a year and could kill 10 million by 2050, yet Sanofi, Novartis, Eli Lilly and AstraZeneca have all quit antibiotic research - because a new antibiotic costs $1.1 billion to build, earns back maybe $100 million, breaks even in year 23, and biology kills it by year 20. The twist is Wockhardt, a Mumbai company that bet $800 million of insulin revenue on a 30-year project and built six novel antibiotics for less than the price of one - including Zaynich, a drug targeting the deadliest drug-resistant hospital infections, valued at $9 billion on its own against the company's $3 billion market cap, with zero competition expected for 15 years. FULL COVERAGE: the captions appear to cover the entire episode. All statistics are the video's own assertions; drug and company names are transcribed from auto-captions and may be approximate (e.g. 'penicellin' for penicillin, 'Wakard' for Wockhardt). Sponsor: Odoo (mid-roll segment). Nothing here is medical advice - do not start, stop or change any medication based on this content.
Executive Summary (TL;DR)
Why did every pharma giant abandon the world's most important drug? Because antibiotics are the rare business where the better product sells less: doctors withhold the strongest drugs to slow resistance, courses last days not years, generics copy instantly, and resistance makes the drug obsolete around year 20 - three years before it breaks even. Meanwhile superbugs kill one Indian baby roughly every 9 minutes, and India - the world's largest antibiotic consumer - is projected to carry 20% of superbug deaths by 2050. Against that backdrop, Wockhardt's Habil Khorakiwala did the 'stupid' thing 30 years ago: poured insulin profits into antibiotic R&D, survived two near-bankruptcies, and emerged with six novel antibiotics for $800 million and a potential 15-year monopoly on Zaynich. The lessons: execution makes you big but R&D makes you irreplaceable; the biggest profits hide where everyone else is too scared to go; and a boring cash cow is what funds a bold bet. FULL COVERAGE: captions appear complete. Sponsor: Odoo. Not medical advice.